Havrix Junior

Havrix Junior is a prescription, inactivated hepatitis A vaccine containing hepatitis A virus antigen and algeldrate as an adjuvant. It is supplied as a sterile injectable solution for intramuscular or subcutaneous administration. Marketed in the European Union, the product is intended for active immunization against hepatitis A infection. The formulation does not contain a listed drug strength, as dosing is determined according to age‑based schedules.

Havrix Junior is indicated for the prevention of hepatitis A infection in children according to approved immunization schedules.

- Primary prophylaxis for hepatitis A in children aged 12 months to 15 years. - Use in outbreak settings to quickly confer immunity to susceptible pediatric populations. - Administration as part of combination vaccination programs when recommended by health authorities. - Boosting of immunity in previously vaccinated children who require a booster dose. - Travel-related protection for children traveling to regions with high hepatitis A endemicity.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines. These reactions are generally self‑limiting and resolve without medical intervention.

Common: - Mild pain, redness, or swelling at the injection site. - Low‑grade fever occurring within 24‑48 hours after vaccination. - Transient fatigue or irritability in young children. - Headache or mild muscle aches. - Mild gastrointestinal upset such as nausea or loss of appetite. - Temporary redness or warmth extending slightly beyond the injection site.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Neurological events including Guillain‑Barré syndrome, though rare. - Severe local reaction with necrosis or abscess formation at the injection site (very rare).

Before administering Havrix Junior, healthcare providers should evaluate several precautionary factors to ensure safe use.

- Confirm that the child has no known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Assess for immunocompromised status; vaccine may be less effective but is not contraindicated. - Review pregnancy status of the mother; safety data in pregnancy are limited. - Avoid vaccination in children with a history of Guillain‑Barré syndrome following a previous hepatitis A vaccine. - Observe the child for at least 15 minutes after injection for immediate hypersensitivity reactions.

Havrix Junior has a limited potential for drug interactions, but certain concomitant therapies warrant attention.

Avoid: - Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) in the same anatomical site; separate sites or intervals are recommended.

Use with caution: - Immunosuppressive agents (e.g., corticosteroids, chemotherapy) may reduce the antibody response to the vaccine. - Antipyretics such as acetaminophen or ibuprofen can be used to manage post‑vaccination fever, but routine prophylactic use may blunt the immune response. - Blood products or immunoglobulins given within 4 weeks before or after vaccination may interfere with seroconversion. - Concurrent administration of other inactivated vaccines is generally acceptable, but monitoring for additive local reactions is advised.